New antibody drug combo targets Hard-to-Treat cancers

NCT ID NCT05123482

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 5 times

Summary

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose cancer has spread or returned after standard treatment will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD8205 (an antibody drug conjugate) and AZD2936 (Rilvegostomig, a bispecific antibody)
What this could lead to: If it works, this could provide a new treatment option for several advanced cancers that have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) focused on safety and dosing, so it is not yet known if AZD8205 will be effective. Side effects are possible, and the drug may not work for all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bile duct carcinoma biliary tract cancer breast cancer breast neoplasm endometrial cancer endometrium neoplasm neoplasm non-small cell squamous lung carcinoma ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CARCINOMA BREAST CANCER ENDOMETRIAL CANCER OVARIAN CANCER SQUAMOUS NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Research Site
COMPLETED

Duarte, California, 91010, United States
Research Site
COMPLETED

Irvine, California, 92618, United States
Research Site
RECRUITING

Santa Monica, California, 90404, United States
Research Site
RECRUITING

Santa Rosa, California, 95403, United States
Research Site
COMPLETED

Shreveport, Louisiana, 71103, United States
Research Site
RECRUITING

Baltimore, Maryland, 21231, United States
Research Site
RECRUITING

Boston, Massachusetts, 02215, United States
Research Site
RECRUITING

St Louis, Missouri, 63110, United States
Research Site
RECRUITING

Albuquerque, New Mexico, 87109, United States
Research Site
RECRUITING

Commack, New York, 11725, United States
Research Site
WITHDRAWN

New York, New York, 10029, United States
Research Site
RECRUITING

Charlotte, North Carolina, 28204, United States
Research Site
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
Research Site
RECRUITING

Houston, Texas, 77030, United States
Research Site
TERMINATED

Clayton, 3168, Australia
Research Site
RECRUITING

Melbourne, VIC 3000, Australia
Research Site
ACTIVE_NOT_RECRUITING

Nedlands, 6009, Australia
Research Site
RECRUITING

Anderlecht, 1070, Belgium
Research Site
RECRUITING

Leuven, 3000, Belgium
Research Site
RECRUITING

Calgary, Alberta, T2N 5G2, Canada
Research Site
RECRUITING

Vancouver, British Columbia, V5Z 4E6, Canada
Research Site
RECRUITING

Ottawa, Ontario, K1H 8L6, Canada
Research Site
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Research Site
COMPLETED

Montreal, Quebec, H4A 3J1, Canada
Research Site
COMPLETED

Beijing, 100142, China
Research Site
RECRUITING

Beijing, 100142, China
Research Site
TERMINATED

Changsha, 410013, China
Research Site
RECRUITING

Changsha, 410013, China
Research Site
RECRUITING

Chongqing, 400030, China
Research Site
COMPLETED

Guangzhou, 510060, China
Research Site
RECRUITING

Kunming, 650118, China
Research Site
RECRUITING

Shandong, China
Research Site
WITHDRAWN

Budapest, 1062, Hungary
Research Site
RECRUITING

Budapest, 1082, Hungary
Research Site
RECRUITING

Budapest, 1122, Hungary
Research Site
RECRUITING

Milan, 20141, Italy
Research Site
RECRUITING

Milan, 20159, Italy
Research Site
RECRUITING

Modena, 41125, Italy
Research Site
RECRUITING

Roma, 00168, Italy
Research Site
RECRUITING

Chūōku, 104-0045, Japan
Research Site
RECRUITING

Hidaka-shi, 350-1298, Japan
Research Site
RECRUITING

Kashiwa, 277-8577, Japan
Research Site
RECRUITING

Kōtoku, 135-8550, Japan
Research Site
RECRUITING

Kurume-shi, 830-0011, Japan
Research Site
RECRUITING

Sunto-gun, 411-8777, Japan
Research Site
RECRUITING

Amsterdam, 1066 CX, Netherlands
Research Site
RECRUITING

Gdansk, 80-214, Poland
Research Site
RECRUITING

Warsaw, 02-781, Poland
Research Site
RECRUITING

Seoul, 03080, South Korea
Research Site
RECRUITING

Seoul, 03722, South Korea
Research Site
RECRUITING

Seoul, 05505, South Korea
Research Site
RECRUITING

Seoul, 06351, South Korea
Research Site
RECRUITING

Barcelona, 8035, Spain
Research Site
RECRUITING

L'Hospitalet de Llobregat, 08908, Spain
Research Site
RECRUITING

Madrid, 28027, Spain
Research Site
RECRUITING

Málaga, 29010, Spain
Research Site
RECRUITING

Pamplona, 31008, Spain
Research Site
RECRUITING

Taichung, 40705, Taiwan
Research Site
RECRUITING

Tainan, 704, Taiwan
Research Site
RECRUITING

Taipei, 10002, Taiwan
Research Site
RECRUITING

Taipei, 11259, Taiwan
Research Site
RECRUITING

Taoyuan, 333, Taiwan
Research Site
RECRUITING

Bangkok, 10330, Thailand
Research Site
RECRUITING

Chiang Mai, 50200, Thailand
Research Site
RECRUITING

Cambridge, CB2 0XY, United Kingdom
Research Site
COMPLETED

Cardiff, CF14 2TL, United Kingdom
Research Site
RECRUITING

London, EC1A 7BE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.